Abstract
The hallmarks of systemic sclerosis (SSc) are autoimmunity, microangiopathy and fibrosis. Skin fibrosis is accompanied by attrition of the dermal white adipose tissue layer, and alterations in the levels and function of adiponectin. Since these findings potentially implicate adiponectin in the pathogenesis of SSc, we employed a novel pharmacological approach to augment adiponectin signaling using AdipoRon, an orally active adiponectin receptor agonist. Chronic treatment with AdipoRon significantly ameliorated bleomycin-induced dermal fibrosis in mice. AdipoRon attenuated fibroblast activation, adipocyte-to-myofibroblast transdifferentiation, Th2/Th17-skewed polarization of the immune response, vascular injury and endothelial-to-mesenchymal transition within the lesional skin. In vitro, AdipoRon abrogated profibrotic responses elicited by TGF-β in normal fibroblasts, and reversed the inherently-activated profibrotic phenotype of SSc fibroblasts. In view of these broadly beneficial effects on all three cardinal pathomechanisms underlying the clinical manifestations of SSc, pharmacological augmentation of adiponectin signaling might represent a novel strategy for the treatment of SSc.
Original language | English (US) |
---|---|
Article number | 11843 |
Journal | Scientific reports |
Volume | 8 |
Issue number | 1 |
DOIs | |
State | Published - Dec 1 2018 |
Funding
Supported by grants from the National Institutes of Health (AR-42309), the National Research Program (Ministry of Higher Education, Science and Technology of Slovenia, #P3-0314), Fulbright Foreign Student Program and the Association for the Development of Rheumatology, Slovenia. This work was supported by a grant for Research on Intractable Diseases from the Ministry of Health, Labor, and Welfare of Japan.
ASJC Scopus subject areas
- General